ESTRO 36 Abstract Book

S746 ESTRO 36 _______________________________________________________________________________________________

7.27 ± 1.07 months (p = 0.000). The primary diagnosis: lung 6.96 ± 1.34 months, breast 5.38 ± 1.47 months, colorectal 5.72 ± 2.19 months (p = 0.016). The histology: adenocarcinoma 7.93 ± 1.99 months, infiltrating ductal 5.36 ± 1.47 months, small cell 4.94 ± 1.07 months, and epidermoid 3.08 ± 1.0 months, (p = 0.004). In patients with breast cancer estrogen and progesterona receptors, negative 1.54 ± 1.3 months and positive 9.8 ± 1.03 months In patients with brain metastases, the best prognosis are lung cancer, adenocarcinoma, ECOG 0, and in breast cancer are positive estrogen and progesterona receptors. EP-1394 Prognostic factor for palliative radiotherapy of bone metastases in good performance-status patients Y. Hamamoto 1 , S. Taguchi 2 , T. Manabe 2 , H. Kanzaki 1 , K. Nagasaki 1 , N. Takata 1 , T. Mochizuki 1 1 Ehime University, Radiology, Toon-city, Japan 2 Saiseikai Imabari Hospital, Radiology, Imabari-city, Japan Purpose or Objective Performance status is well-known prognostic factor for patients received palliative care. Regarding patients with good performance status, prognostic factors after palliative intent radiation therapy (PIRT) were investigated. Material and Methods Between Dec. 2009 and Mar. 2014, 148 patients received initial PIRT in our institution. Of these, 100 patients were able to be followed up until death or for more than six months. Among these 100 patients, 63 patients (age, 58- 89, median 69; male/female=45/18) were in good performance status (PS 0-1), and were reviewed in this study. Survival time was calculated from the initiation of initial PIRT. Assessed factors were age (<75 vs. >75), sex, primary sites (breast vs. other organs), sites of initial PIRT (bone/soft-tissue/lymph-nodes vs. other organs), and administration of chemotherapy before PIRT (yes vs. no). Univariate analysis was performed by log-rank test and multivariate analysis was performed by Cox proportional hazard model. Results Regarding all 63 patients, median survival time was seven months and the 1-year overall survival rate was 34%. On univariate analysis, irradiate sites was the only statistically significant factor for survival after PIRT (p=0.0159). Irradiate sites was the statistically significant factor also on multivariate analysis (p=0.0179). The 1-year overall survival rate of the patients who received PIRT to bone/soft-tissue/lymph-nodes was 46% (median survival time, 11 months), while that was 15% for the patients who received PRIT to other organs (median survival time, 4 months). Conclusion With regard to patients with good performance status, prognosis of patients who received PIRT to bone/soft- tissue or lymph-nodes was comparatively good. Despite small patient number of this study, it seemed that extremely hypofractionated PIRT was not suitable for these patients. EP-1395 CyberKnife treatment of intraorbital metastases: a single center experience on 24 lesions. G. Riva 1 , M. Augugliaro 1 , G. Piperno 1 , A. Ferrari 1 , E. Rondi 1 , S. Vigorito 1 , R. Orecchia 1 , B.A. Jereczek-Fossa 1 1 Istituto Europeo di Oncologia - IEO, Radiotherapy, MIlan, Italy Purpose or Objective The aim of the study is to evaluate the feasibility, acute toxicity and symptoms control of CyberKnife (Accuray, (p=0.025). Conclusion

Sunnyvale, CA)-based stereotactic radiotherapy (CBK-SRT) on intraorbital metastases. Material and Methods This retrospective analysis included patients (pts) with symptomatic metastases located wholly within the orbit. Palliative radiation treatment was performed using CyberKnife image-guided technology (using skull-tracking technique). Gross tumor volume (GTV) volume was defined on a pre-radiotherapy magnetic resonance imaging (MRI) with Gadolinium. Treated volumes and dose-volume histograms (DVHs) are discussed. Acute toxicity was recorded according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) Scale. Results Between April 2012 and July 2016, 24 metastases (21 pts, 3 treated bilaterally) underwent CBK-SRT for intraorbital lesions (10 intraocular, 14 periocular) from different primary tumors (breast in 13 pts, lung in 3 pts, kidney in 2 pts, lymphoma in 1 pts, thyroid in 1 pts, trunk leiomyosarcoma in 1 pts). The median treatment dose was 18 Gy (range, 15-24 Gy) given over a median of 3 fractions (range, 2-3 fractions) with a median dose of 6 Gy per fraction (range, 5-10 Gy/fraction). Treated volumes and DVHs are reported in Table 1. At the end of the treatment, grade 1 toxicity according to RTOG/EORTC score was observed in 8 cases. No change in visual field or loss of vision was documented. 13 lesions of 24 had undergone post-radiotherapy MRI and after median follow-up of 6 months (range, 2.0-26.5 months) no local recurrence occurred. All of these patients reported decreasing pre-radiotherapy symptoms and improvement in quality of life. Longer follow-up (more than 12 months) is available in 4 lesions with complete radiological response in all cases.

Conclusion In our experience, CyberKnife radiotherapy is a well- tolerated, safe and efficacious technique for palliative treatment of intraocular and periocular metastases.